666

大摩:予药明生物“增持”评级 目标价升3.6%至170港元

大摩发布研究报告称,予药明生物(02269)“增持”评级,目标价自164港元上调至170港元,上调2021-24年间盈测1%至9%,以反映强劲上半年业绩表现,收入及毛利润预测也同步上调。 ...
大摩:予药明生物“增持”评级 目标价升3.6%至170港元

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

  • Top
  • Latest
empty
No comments yet